


**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims:**

What is claimed is:

Claim 1 (Currently Amended): A method of treating a susceptible cancer in a mammal, comprising: administering to said mammal therapeutically effective amounts of (i) ~~at least one erb family inhibitor~~ a compound of formula (I)



or a salt, solvate, physiologically functional derivative thereof;

wherein

Y is CR<sup>1</sup> and V is N;

or Y is CR<sup>1</sup> and V is CR<sup>2</sup>;

R<sup>1</sup> represents a group CH<sub>3</sub>SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>-Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy groups;


R<sup>2</sup> is selected from the group comprising hydrogen, halo, hydroxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylamino and di[C<sub>1-4</sub> alkyl]amino;

U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R<sup>3</sup> group and optionally substituted by at least one independently selected R<sup>4</sup> group;

R<sup>3</sup> is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;

or R<sup>3</sup> represents trihalomethylbenzyl or trihalomethylbenzyloxy;

or R<sup>3</sup> represents a group of formula




wherein each R<sup>5</sup> is independently selected from halogen, C<sub>1-4</sub> alkyl and C<sub>1-4</sub> alkoxy; and n is 0 to 3;

each R<sup>4</sup> is independently hydroxy, halogen, C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, amino, C<sub>1-4</sub> alkylamino, di[C<sub>1-4</sub> alkyl]amino, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulphinyl, C<sub>1-4</sub> alkylsulphonyl, C<sub>1-4</sub> alkylcarbonyl, carboxy, carbamoyl, C<sub>1-4</sub> alkoxy carbonyl, C<sub>1-4</sub> alkanoylamino, N-(C<sub>1-4</sub> alkyl)carbamoyl, N,N-di(C<sub>1-4</sub> alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and

(ii) at least one Raf and/or ras inhibitor.

Claim 2 (Cancelled):

Claim 3 (Original): A method of treating a susceptible cancer in a mammal, comprising: administering to said mammal therapeutically effective amounts of (i) a compound of formula (I)



or a salt, solvate, physiologically functional derivative thereof;

wherein

Y is CR<sup>1</sup> and V is N;

or Y is CR<sup>1</sup> and V is CR<sup>2</sup>;

R<sup>1</sup> represents a group CH<sub>3</sub>SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>-Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy groups;


R<sup>2</sup> is selected from the group comprising hydrogen, halo, hydroxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylamino and di[C<sub>1-4</sub> alkyl]amino;

U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R<sup>3</sup> group and optionally substituted by at least one independently selected R<sup>4</sup> group;

R<sup>3</sup> is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;

or R<sup>3</sup> represents trihalomethylbenzyl or trihalomethylbenzyloxy;

or R<sup>3</sup> represents a group of formula




wherein each R<sup>5</sup> is independently selected from halogen, C<sub>1-4</sub> alkyl and C<sub>1-4</sub> alkoxy; and n is 0 to 3;

each R<sup>4</sup> is independently hydroxy, halogen, C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, amino, C<sub>1-4</sub> alkylamino, di[C<sub>1-4</sub> alkyl]amino, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulphinyl, C<sub>1-4</sub> alkylsulphonyl, C<sub>1-4</sub> alkylcarbonyl, carboxy, carbamoyl, C<sub>1-4</sub> alkoxy carbonyl, C<sub>1-4</sub> alkanoylamino, N-(C<sub>1-4</sub> alkyl)carbamoyl, N,N-di(C<sub>1-4</sub> alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and

(ii) a cRaf-1 inhibitor.


Claim 4 (Original): A method of treating a susceptible cancer in a mammal, comprising: administering to said mammal therapeutically effective amounts of (i) a compound of formula (II):



and salt or solvates thereof, wherein R is -Cl or -Br, X is CH, N, or CF, and Z is thiazole or furan; and

(ii) a cRaf-1 inhibitor.


Claim 5 (Original): A method of treating a susceptible cancer in a mammal, comprising: administering to said mammal therapeutically effective amounts of (i) a compound of formula (III):



and salts or solvates thereof; and

(ii) a cRaf-1 inhibitor.

Claim 6 (Currently Amended): A cancer treatment combination, comprising: therapeutically effective amounts of (i) ~~at least one erb family inhibitor~~ a compound of formula (I)



or a salt, solvate, physiologically functional derivative thereof;

wherein

Y is CR<sup>1</sup> and V is N;

or Y is CR<sup>1</sup> and V is CR<sup>2</sup>;

R<sup>1</sup> represents a group CH<sub>3</sub>SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>-Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy groups;


R<sup>2</sup> is selected from the group comprising hydrogen, halo, hydroxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylamino and di[C<sub>1-4</sub> alkyl]amino;

U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R<sup>3</sup> group and optionally substituted by at least one independently selected R<sup>4</sup> group;

R<sup>3</sup> is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;

or  $R^3$  represents trihalomethylbenzyl or trihalomethylbenzyloxy;

or  $R^3$  represents a group of formula




wherein each  $R^5$  is independently selected from halogen,  $C_{1-4}$  alkyl and  $C_{1-4}$  alkoxy; and n is 0 to 3;

each  $R^4$  is independently hydroxy, halogen,  $C_{1-4}$  alkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{1-4}$  alkoxy, amino,  $C_{1-4}$  alkylamino, di[ $C_{1-4}$  alkyl]amino,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylsulphinyl,  $C_{1-4}$  alkylsulphonyl,  $C_{1-4}$  alkylcarbonyl, carboxy, carbamoyl,  $C_{1-4}$  alkoxy carbonyl,  $C_{1-4}$  alkanoylamino, N-( $C_{1-4}$  alkyl)carbamoyl, N,N-di( $C_{1-4}$  alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and

(ii) at least one Raf and/or ras inhibitor.

Claim 7 (Cancelled):

Claim 8 (Original): A cancer treatment combination, comprising: therapeutically effective amounts of (i) a compound of formula (I)



or a salt, solvate, or physiologically functional derivative thereof;

wherein

Y is  $CR^1$  and V is N;

or Y is  $CR^1$  and V is  $CR^2$ ;

$R^1$  represents a group  $CH_3SO_2CH_2CH_2NHCH_2-Ar-$ , wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo,  $C_{1-4}$  alkyl or  $C_{1-4}$  alkoxy groups;


$R^2$  is selected from the group comprising hydrogen, halo, hydroxy,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylamino and di[ $C_{1-4}$  alkyl]amino;

U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an  $R^3$  group and optionally substituted by at least one independently selected  $R^4$  group;

$R^3$  is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;

or  $R^3$  represents trihalomethylbenzyl or trihalomethylbenzyloxy;

or  $R^3$  represents a group of formula




wherein each  $R^5$  is independently selected from halogen,  $C_{1-4}$  alkyl and  $C_{1-4}$  alkoxy; and n is 0 to 3;

each  $R^4$  is independently hydroxy, halogen,  $C_{1-4}$  alkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{1-4}$  alkoxy, amino,  $C_{1-4}$  alkylamino, di[ $C_{1-4}$  alkyl]amino,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylsulphinyl,  $C_{1-4}$  alkylsulphonyl,  $C_{1-4}$  alkylcarbonyl, carboxy, carbamoyl,  $C_{1-4}$  alkoxycarbonyl,  $C_{1-4}$  alkanoylamino, N-( $C_{1-4}$  alkyl)carbamoyl, N,N-di( $C_{1-4}$  alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and

(ii) a cRaf-1 inhibitor.


Claim 9 (Original): A cancer treatment combination, comprising: therapeutically effective amounts of (i) a compound of formula (II):



and salt or solvates thereof, wherein R is -Cl or -Br, X is CH, N, or CF, and Z is thiazole or furan; and

(ii) a cRaf-1 inhibitor.

Claim 10 (Original): A cancer treatment combination, comprising: therapeutically effective amounts of (i) a compound of formula (III):




and salts or solvates thereof; and

(ii) a cRaf-1 inhibitor.

Claims 11-15 (Cancelled):

Claim 16 (Original): A method of treating a susceptible cancer in a mammal, comprising: administering to said mammal therapeutically effective amounts of (i) a compound of formula (I)





or a salt, solvate, physiologically functional derivative thereof;

wherein

Y is CR<sup>1</sup> and V is N;

or Y is CR<sup>1</sup> and V is CR<sup>2</sup>;

R<sup>1</sup> represents a group CH<sub>3</sub>SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>-Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy groups;


R<sup>2</sup> is selected from the group comprising hydrogen, halo, hydroxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylamino and di[C<sub>1-4</sub> alkyl]amino;

U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R<sup>3</sup> group and optionally substituted by at least one independently selected R<sup>4</sup> group;

R<sup>3</sup> is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;

or R<sup>3</sup> represents trihalomethylbenzyl or trihalomethylbenzyloxy;

or R<sup>3</sup> represents a group of formula




wherein each  $R^5$  is independently selected from halogen,  $C_{1-4}$  alkyl and  $C_{1-4}$  alkoxy; and  $n$  is 0 to 3;

each  $R^4$  is independently hydroxy, halogen,  $C_{1-4}$  alkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{1-4}$  alkoxy, amino,  $C_{1-4}$  alkylamino, di[ $C_{1-4}$  alkyl]amino,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylsulphinyl,  $C_{1-4}$  alkylsulphonyl,  $C_{1-4}$  alkylcarbonyl, carboxy, carbamoyl,  $C_{1-4}$  alkoxy carbonyl,  $C_{1-4}$  alkanoylamino, N-( $C_{1-4}$  alkyl)carbamoyl, N,N-di( $C_{1-4}$  alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and


(ii) a bRaf inhibitor.

Claim 17 (Original): A method of treating a susceptible cancer in a mammal, comprising: administering to said mammal therapeutically effective amounts of (i) a compound of formula (II):



and salt or solvates thereof, wherein  $R$  is  $-Cl$  or  $-Br$ ,  $X$  is  $CH$ ,  $N$ , or  $CF$ , and  $Z$  is thiazole or furan; and (ii) a bRaf inhibitor.

Claim 18 (Original): A method of treating a susceptible cancer in a mammal, comprising: administering to said mammal therapeutically effective amounts of (i) a compound of formula (III):




and salts or solvates thereof; and

(ii) a bRaf inhibitor.

Claim 19 (Cancelled):

Claim 20 (Original): A cancer treatment combination, comprising:  
therapeutically effective amounts of (i) a compound of formula (I)



or a salt, solvate, or physiologically functional derivative thereof;

wherein

Y is CR<sup>1</sup> and V is N;

or Y is CR<sup>1</sup> and V is CR<sup>2</sup>;

R<sup>1</sup> represents a group CH<sub>3</sub>SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>-Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy groups;

R<sup>2</sup> is selected from the group comprising hydrogen, halo, hydroxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylamino and di[C<sub>1-4</sub> alkyl]amino;


U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-

dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R<sup>3</sup> group and optionally substituted by at least one independently selected R<sup>4</sup> group;

R<sup>3</sup> is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;

or R<sup>3</sup> represents trihalomethylbenzyl or trihalomethylbenzyloxy;

or R<sup>3</sup> represents a group of formula




wherein each R<sup>5</sup> is independently selected from halogen, C<sub>1-4</sub> alkyl and C<sub>1-4</sub> alkoxy; and n is 0 to 3;

each R<sup>4</sup> is independently hydroxy, halogen, C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, amino, C<sub>1-4</sub> alkylamino, di[C<sub>1-4</sub> alkyl]amino, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulphinyl, C<sub>1-4</sub> alkylsulphonyl, C<sub>1-4</sub> alkylcarbonyl, carboxy, carbamoyl, C<sub>1-4</sub> alkoxycarbonyl, C<sub>1-4</sub> alkanoylamino, N-(C<sub>1-4</sub> alkyl)carbamoyl, N,N-di(C<sub>1-4</sub> alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and

(ii) a bRaf inhibitor.


Claim 21 (Currently Amended): A cancer treatment combination, comprising: therapeutically effective amounts of (i) a compound of formula (II):



and salt or solvates thereof, wherein R is  $-\text{Cl}$  or  $-\text{Br}$ , X is CH, N, or CF, and Z is thiazole or furan; and

(ii) a ~~bRaf~~ bRaf-1 inhibitor.

Claim 22 (Original): A cancer treatment combination, comprising: therapeutically effective amounts of (i) a compound of formula (III):




and salts or solvates thereof; and


(ii) a bRaf inhibitor.

Claims 23-24 (Cancelled):


Claim 25 (New): The method of claim 1, wherein the compound of formula (I) is the monohydrate ditosylate salt of




Claim 26 (New): The cancer treatment combination of claim 6, wherein the compound of formula (I) is the monohydrate ditosylate salt of




Claim 27 (New): The method of claim 3, wherein the compound of formula (I) is the monohydrate ditosylate salt of



Claim 28 (New): The cancer treatment combination of claim 8, wherein the compound of formula (I) is the monohydrate ditosylate salt of



Claim 29 (New): The method of claim 16, wherein the compound of formula (I) is the monohydrate ditosylate salt of



Claim 30 (New): The method of claim 20, wherein the compound of formula (I) is the monohydrate ditosylate salt of

